Bayer Tagged Articles

Woman recounts nightmare experience with Mirena IUD

Posted: June 17, 2013 Pharmaceutical

It was difficult to see the “cons” with the Mirena IUD, writes Bianca Wordley in The Border Mail. “The small t-shaped IUD works when the hormone levonorgestrel is released, making the mucus in the cervix thicker so that sperm can’t

Affordable Healthcare Act may make more women choose IUDs over pills

Posted: April 22, 2013 Pharmaceutical

Changes in health care laws may help make intrauterine devices (IUDs) more affordable for women, and could boost sales of the devices in the United States.

Woman’s lawsuit claims Mirena IUD caused her serious bodily injury

Posted: March 31, 2013 Pharmaceutical

An Arizona woman has filed a lawsuit against Bayer alleging her intrauterine device for birth control caused her serious bodily injury.

Bayer introduces new hormone-releasing IUD Skyla

Posted: January 15, 2013 Pharmaceutical

The Food and Drug Administration (FDA) has approved a new contraceptive device  made by Bayer HealthCare Pharmaceuticals. Skyla, an intrauterine device (IUD) that releases the hormone levonorgestrel, is placed in the uterus to prevent pregnancy for up to three years.

Anti-clotting drug Eliquis gets FDA approval

Posted: January 3, 2013 Pharmaceutical

Eliquis, a new anti-clotting drug developed by Bristol-Myers Squibb and Pfizer as an alternative to the decades-old warfarin (Coumadin), has finally won approval from the U.S. Food and Drug Administration (FDA).

Bayer expects to reap billions from new blood thinner Xarelto

Posted: November 17, 2012 Pharmaceutical

Bayer is banking on five of its prescription drugs to bring in more than $7 million in annual sales, including its blood thinner Xarelto (rivaroxaban), which is approved for various uses in 120 countries, including the United States. Bayer also

FDA grants new indication for blood thinner Xarelto

Posted: November 6, 2012 Pharmaceutical

The Food and Drug Administration (FDA) has agreed to expand the indication for Bayer and Johnson & Johnson’s new blood thinner Xarelto. The drug can now be used to treat and prevent deep vein thrombosis and pulmonary embolism.

Xarelto makers enjoy huge profits despite bleeding risks

Posted: November 2, 2012 Pharmaceutical

Sales of the blood thinner Xarelto have more than quadrupled compared to prior year quarter to $105 million, and were up $88 million in the second quarter, according to Bayer. Xeralto, a joint effort by Bayer and Johnson & Johnson,

FDA to decide fate of blood thinner Eliquis by March

Posted: October 20, 2012 Pharmaceutical

The Food and Drug Administration (FDA) says it will decide by March 17, 2013, whether to approve Bristol-Myers Squibb Co and Pfizer Inc.’s blood thinner Eliquis for the prevention of strokes in patients with atrial fibrillation. Drug regulators rejected Eliquis

Bayer hopes to expand treatment options for blood thinner Xarelto

Posted: September 10, 2012 Pharmaceutical

Bayer is trying hard to get the Food and Drug Administration (FDA) to agree to expand the treatment options for its new blood thinner Xarelto despite its potential to cause potentially deadly hemorrhaging.